Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy that is predominantly known to affect the ventricles. Evidence for atrial involvement remains limited. Therefore, we aimed to characterize atrial involvement in ARVC using functional cardiac magnetic resonance, define the extent of atrial size and function variation attributable to ventricular variables, and identify cardiac magnetic resonance-based predictors of atrial arrhythmias (AA) in ARVC.
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A rrhythmogenic right ventricular cardiomyopathy (ARVC) is an inheritable heart muscle disorder that predominantly affects the right ventricle (RV) and is one of the leading causes of arrhythmic cardiac arrest in young people and athletes. 1 Progressive loss of RV myocardium and its replacement by fibrofatty tissue is the pathological hallmark of the disease. 2 ARVC is predominantly characterized as a disease of the cardiac desmosome, which is a complex of structural proteins providing mechanical support to myocytes. 3 Despite desmosomes being found throughout the cardiac system, including the atria, evidence for direct atrial involvement with ARVC remains limited. In addition, few studies have focused on atrial arrhythmias (AA) such as atrial fibrillation and atrial flutter in patients with ARVC, despite its higher incidence compared with the general population. 4, 5 A recent study by Mazzanti et al 6 brought to light the important prognostic value of AA on incident life-threatening arrhythmias and cardiovascular mortality in this patient population. In a previous study, we identified genotype-specific differences in atrial volumes using conventional cardiac magnetic resonance imaging (CMR) in a large cohort of ARVC patients, suggesting presence of primary atrial involvement in ARVC. 7 We hypothesized that structural and functional abnormalities in the atria may be observed using tissue-tracking CMR in ARVC patients free of clinically manifest AA and heart failure.
In a large prospective cohort of ARVC patients without AA and overt heart failure at baseline, we aim (1) to characterize atrial involvement in ARVC patients compared with controls and (2) to detect predictors of AA in ARVC patients using CMR tissue-tracking techniques.
METHODS
The data, analytic methods, and study materials will be/have been made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Population
This study is a post hoc analysis of our recently described patient population. 7 In our prior study, we had included 71 participants who fulfilled the 2010 diagnostic Task Force Criteria (TFC) for ARVC 8 ). For this present study, ARVC patients who had AA before CMR (n=3) and those who had overt congestive heart failure (New York Heart Association functional classification ≥3; n=2) were excluded. As such, the final study population consisted of 66 definite ARVC patients identified from the University Medical Center ARVC registry in Utrecht, The Netherlands. The demographics and diagnostic TFC of these patients are described in Table 1 . As a control group, we included 24 individuals with no identifiable cardiovascular disease after a comprehensive clinical evaluation at the Center of Excellence for ARVC and Complex Ventricular Arrhythmias of the Johns Hopkins Hospital (Baltimore). The study was approved by the local institutional review boards, and all patients provided written consent.
CMR Acquisition
Cine CMR images were acquired on a 1.5-T MRI scanner (Achieva, Philips [ARVC patients] and Avanto, Siemens Medical Imaging [control participants]). In short, we performed ECGgated breathhold steady-state-free precession cine images (2-chamber RV and left ventricle [LV], LV and RV outflow tract, and stacks of 4-chamber and short-axis images for complete atrial and ventricular coverage), axial T1-weighted black-blood images, quantitative flow measurement using phase-contrast through-plane velocity mapping over the tricuspid and pulmonary valves, and phase-sensitive inversion recovery late gadolinium enhancement images. Field of view of CMR images was "CMR Images had a field of view of 350 mm with a matrix size of 256×256 and a slice thickness of 8 mm (1.3×1.3×8 mm 3 )." The temporal resolution of both the 2-and 4-chamber view was 40 to 50 ms.
CMR Analysis

Atrial Analysis
We used Multimodality Tissue Tracking software (version 6.0, Toshiba, Japan) to measure phasic left atrial (LA) and right
CLINICAL PERSPECTIVE
Uncovering atrial involvement in arrhythmogenic right ventricular cardiomyopathy gives important mechanistic insight into the disease and its natural progression. Arrhythmogenic right ventricular cardiomyopathy patients with atrial fibrillation may have higher propensity toward embolic cerebrovascular accidents by virtue of their fibrillatory atria. Most arrhythmogenic right ventricular cardiomyopathy patients get early cardiac magnetic resonance study for diagnosis/classification; therefore, the ability to characterize atrial dysfunction in the pre-atrial fibrillation stage may offer an opportunity for stroke prevention (although further studies are needed to show the benefit of such prophylaxis). Increased risk of atrial arrhythmias dictates proper implantable cardioverter-defibrillator programming and device selection. Indeed, potential overlap of ventricular rates with atrial arrhythmias and ventricular tachycardia requires careful device programming to minimize risk of inappropriate implantable cardioverter-defibrillator shocks. A lower threshold for atrial lead insertion to increase device diagnostic capabilities and accuracy may be warranted in patients who are found to have early atrial remodeling on functional cardiac magnetic resonance.
atrial (RA) volumes, strain, and strain rate using 4-chamber and 2-chamber cine images. As previously described for LA functional analysis, 9 we manually contoured myocardial borders as seen in Figure 1 . The trabecular region of the RA appendage, which results in poor tracking, was excluded from analysis. The software then propagated these borders across the cardiac cycle automatically using a template matching algorithm. The software recorded a characteristic pixel pattern of each 10×10 mm square area in the reference frame; an area with identical pixel pattern was recognized in the next frame that maximized the similarity evaluated by cross-correlation between the square areas. This procedure was repeated for all pixels in each image and for each frame to track the borders throughout the whole cardiac cycle. 9 Manual adjustments were performed when tracking was suboptimal. After confirming accurate tracking, global RA and LA peak longitudinal strain and strain rate curves were generated automatically by averaging strain and strain rate measurements in all segments. Peak longitudinal atrial strain (PLAS), peak systolic strain rate (SR s ), peak early-diastolic strain rate (SR ed ), and peak late-diastolic strain rate (SR ld ) were calculated as shown in Figure 2 . The SR ed and SR ld are negative values by convention and were presented as absolute values in this article. Phasic volume curves were generated to identify maximum, pre-contraction, and minimum atrial volumes as shown in Figure 2 . RA and LA volumes (RAV and LAV) were indexed for the body surface area as calculated by the DuBois formula. Total, passive, and active atrial emptying fractions were measured using the following calculations:
• Total atrial emptying fraction: 100×(atrial maximum volume−atrial minimum volume)/atrial maximum volume.
• Passive atrial emptying fraction: 100×(atrial maximum volume−atrial precontraction volume)/atrial maximum volume.
• Active atrial emptying fraction: 100×(atrial pre-contraction volume−atrial minimum volume)/atrial precontraction volume. The PLAS, SR s , and total emptying fraction represent atrial reservoir function; passive emptying fraction and SR ed represent atrial conduit function; SR ld and active emptying fraction represent atrial pump function.
Our group has previously shown excellent inter-and intraobserver reproducibility of our atrial strain analysis technique with the Multimodality Tissue Tracking software (Toshiba, Japan).
9,10
Global Ventricular Size and Function
Ventricular metrics and ejection fraction (EF) were measured using semiautomated contour tracing software (View Forum cardiac package version R5.1V1L2.SP3, Phillips). Ventricular end-diastolic volume (EDV) and end-systolic volume were indexed for body surface area.
Postprocessing analysis was performed by an observer who was blinded to the AA outcome of the study participants.
Atrial Arrhythmias
The diagnosis of ARVC was based on the 2010 revised TFC. 8 ARVC was diagnosed when ≥4 TFC points from different categories were fulfilled; thus 2 major, 1 major plus 2 minor, or 4 minor criteria sufficed for a definite ARVC diagnosis. The primary outcome of this study was the time to occurrence of the first episode of AA (atrial fibrillation or atrial flutter) lasting ≥30 s from baseline (time of CMR study). This was recorded by 12-lead ECG, Holter monitoring, or implantable cardioverter-defibrillator (ICD) interrogation during clinical follow-up at the discretion of the managing physician.
Statistical Analysis
Continuous and discrete data are presented as mean (±SD) and n (%), respectively. Continuous data comparison of 2 groups were performed Wilcoxon rank-sum test given the small sample size, and binary variables were compared using χ 2 analysis. Multivariable Cox proportional hazards models were used to determine the association with time-to-incident AA during follow-up. To avoid collinearity, correlations between continuous variables were tested using the Pearson correlation coefficient before fitting any 2 independent variables in the same model. Among the pool of collinear variables (r>0.50), the parameters with the strongest association with the outcome were selected for inclusion in the model using Akaike information criterion for inclusion in the multivariable model. A separate Cox proportional hazards multivariable model was constructed for each RA/LA functional and structural parameter. To ensure that our results are not affected by overfitting, we performed 2 multivariable analyses as follows: model 1 was adjusted for age at CMR and number of TFC, whereas model 2 was adjusted for age, sex, Peak right and left atrial longitudinal strain and strain rate curves were generated automatically by averaging strain and strain rate measurements in all segments. Peak longitudinal atrial strain (PLAS), peak systolic strain rate (SRs), peak early-diastolic strain rate (SR ed ), and peak late-diastolic strain rate (SR ld ) were calculated as shown.
hypertension, body surface area, number of TFC, as well as LV/RV EDV i and EF. After selecting the parameters with the highest predictive value (lowest Akaike information criterion), we plotted Kaplan-Meier curves displaying AA-free survival rates from baseline (time of CMR) stratified by the median value of these parameters. Two-sided P values <0.05 were considered statistically significant. Statistical analysis was performed using STATA software (version 13; StataCorp, College Station, TX).
RESULTS
Study Population Characteristics
We included 66 patients with definite ARVC and 24 control participants with structurally normal hearts. Overall, 58% of ARVC patients and 63% of control participants were male with a mean age of 46.3±15.7 and 38.2±15.8 years, respectively. As seen in Table 1 , there were no significant differences between ARVC patients and controls in sex (P=0.89), age (P=0.10), and body surface area (P=0.65). The distribution of the TFC in the ARVC patients is described in Table 1 .
CMR Analysis
CMR structural and functional ventricular and atrial measurements of the study participants are summarized in Table 2 . Comparison between ARVC patients and control participants is also displayed in Figure 3 . As expected, ARVC patients had higher indexed RV volumes (RV-EDV(i), 123.6±38.2 mL/m 2 ) and lower RV function (RVEF, 39.4±10.3%) compared with controls 
Atrial Arrhythmias
Among the 66 ARVC patients, 14 (21%) individuals experienced ≥1 types of AA during a median follow-up of 6.8 years [interquartile range, 3.0-10.8 years]. In 7 of 14 patients, the first AA episode was recorded by 12-lead ECG (after complaints of the patient), in 6 of 14 by ICD interrogation (2 discovered after inappropriate ICD intervention), and in 1 with 24-hour Holter monitoring. Clinical characteristics of arrhythmias in this cohort were previously described by our group. 9 In brief, atrial fibrillation was the most common type of arrhythmia occurring in 11 (79%) patients, atrial flutter occurred in 2 (14%), and 1 (7%) patient experienced both types of AA. Median age at first AA was 57.3 [interquartile range, 42.0-67.4] years. Compared with those without AA, patients with arrhythmias were more likely to be male (81% versus 50%; P=0.027) and present with ARVC at an older age (48.9±16.9 years versus 40.1±14.8 years; P= 0.036). Two patients died during follow-up (57 and 64 years of age, both females and carriers of PLN mutation). One patient had developed AA during follow-up. Cause of death was traumatic intracranial hemorrhage during an episode of ventricular tachycardia in 1 patient and decompensated heart failure in the other patient. Table 4 summarizes univariable and multivariable Cox regression analyses performed to predict subsequent AAs in our cohort. Atrial parameters with a Pearson coefficient >0.5 were excluded from the model to avoid collinearity as described in the methods. Because indexed RA volumetric parameters were highly collinear, only RAV min (which had the strongest association with the outcome) was included in the multivariable analysis. All RAEF parameters (total, active, and passive) were collinear; thus only RAEF passive was selected. RA-SR ed was selected for strain measurement, as RA-PLAS, RA-SR s , and RA-SR ed were collinear. A similar collinearity screening was performed for LA (LAV min , LAEF total , and LA-PLAS were selected). As seen in Table 4 , all of RAV min , RAEF passive , RA-SR ed , LAV min , LAEF total , and LA-PLAS were significant predictors of the outcome in both model 1 (adjusted for age at CMR and number of TFC) and model 2 (adjusted for age, sex, hypertension, body surface area, number of TFC, as well as LV/RV EDV i and EF). In fact, higher atrial volumes (10% increased risk per mL for both RAV min and LAV min ; P<0.05), reduced LA reservoir function (LAEF total and LA-PLAS), and reduced RA conduit function (RAEF passive and RA-SR ed ) were associat- 
DISCUSSION
We investigated atrial involvement with ARVC in a large cohort of patients using functional CMR imaging. This study has 2 major findings. First, compared with controls, ARVC patients had significantly higher biatrial volumes, reduced RA conduit function (passive EF [RAEF passive ] and SR ed ), reduced RA and LA reservoir function (SR s ), as well as reduced RA and LA pump function (SR ld ). Second, patients with subsequent AA during follow-up were found to exhibit lower RA and LA function. On multivariable analysis, higher biatrial volumes, decreased LA reservoir function (LAEF total and LA-PLAS) and RA conduit function (RAEF passive and RA-SR ed ) were associated with increased risk of AA during follow-up.
Atrial Involvement in ARVC
Previous studies examining atrial structure and function in ARVC are scarce. Animal studies showed fibrofatty replacement of atrial myocardium in 17% of cat ARVC models and in 35% of dog ARVC models 11 ; and Platonov et al 12 have demonstrated evidence for altered Mean values±SD. P values are derived from mean comparison analysis and not survival analysis and do not account for differing times between cardiac magnetic resonance and outcome/last follow-up. AA indicates atrial arrhythmia; ARVC, arrhythmogenic right ventricular cardiomyopathy; CI, confidence interval; EDV, end-diastolic volume; EF, ejection fraction (%); ESV, end-systolic volume; LA, left atrial; LAV, LA volume; PLAS, peak longitudinal atrial strain (%); RA, right atrial; RAV max (i), maximum right atrial volume index (mm 3 /m 2 ); RAV min (i), minimum right atrial volume index (mm 3 /m 2 ); RAV pre (i), preatrial volume (mm 3 /m 2 ), SR ed , early diastolic strain rate (absolute value), SR ld , late diastolic strain rate (absolute value); and SR s , systolic strain rate (absolute value).
electrical conduction within the atria of ARVC patients. In concordance with our results, Yoerger et al 13 examined echocardiographic structural markers in 29 ARVC patients and found increased RA dimensions compared with age, sex, and body size-matched controls. On echocardiography, RA and LA enlargement were seen in 26% and 14% of patients, respectively (Saguner et al, 14 n=70 patients) and in 32% and 15%, respectively (Camm et al, 4 n=210 patients). On adjusted analysis, RA short-axis diameter was an independent predictor of major adverse cardiovascular outcome during followup.
14 Interestingly, Bourfiss et al 7 found genotype-specific patterns of volumetric changes in ARVC. Significantly larger atria were found in patients with no mutation identified and significantly smaller atria in PKP2 mutation carriers, compared with controls with idiopathic right ventricular outflow tract tachycardia. Recent advances in CMR-based tissue-tracking techniques allow in-depth structural and functional characterization of the atria. 9, 15, 16 The feasibility and reproducibility of CMR-based tissue tracking to analyze atrial dimensions, function, and deformation have been shown in prior studies. 9, [15] [16] [17] To our knowledge, our study is the first to use the capabilities of tissue tracking on functional CMR to characterize atrial size and function in a large cohort of ARVC patients. Our results show that compared with age-matched, sex-matched, and body size-matched healthy controls, ARVC patients had enlarged atria at all stages of the cardiac cycle, as well as stiffer and a poorly contractile atria with reduced RA conduit function, reduced RA and LA reservoir function, as well as reduced RA and LA pump function. This cross-sectional analysis clearly points to primary atrial involvement in ARVC as our patients were free of overt heart failure as well as any history of AA at the time of the scan.
AA in ARVC
The higher incidence of AA in ARVC was reported early in the characterization of the disease. Incidence rate of AA in previous studies ranges from 14% (without ICD) to 42% (with ICD). 5, 18, 19 The negative prognostic implications of AA on mortality and morbidity in ARVC have also been reported. In 301 consecutive patients with ARVC, history of atrial fibrillation was associated with a 4-fold increase in the occurrence of life-threatening arrhythmic events defined as sudden cardiac death, aborted cardiac arrest, syncopal ventricular tachycardia or electrical storm, or cardiovascular mortality. 6 Other studies have also supported the observation that ARVC Each row represents a separate multivariable model for each parameter. Model 1 was adjusted for number of Task Force Criteria (TFC) and age at cardiac magnetic resonance (CMR). Model 2 was adjusted for age at CMR, sex, hypertension, body surface area, number of TFC, RV/LV end-diastolic volume index, and ejection fraction. AA indicates atrial arrhythmia; CI, confidence interval; EF, ejection fraction; HR, hazard ratio; LA, left atrium; LAVmin, minimal left atrial volume; PLAS, peak longitudinal atrial strain; RA, right atrium; RAV min , minimal right atrial volume; and SR ed , early-diastolic strain rate. patients with AAs had increased life-threatening ventricular arrhythmias, inappropriate shocks, heart failure, heart transplants, and cardiovascular mortality compared with those without AAs. 4, 7, 14 The implications of AAs thus underlie the importance of detecting baseline predictors of future AA in patients with early ARVC for an appropriate prevention strategy. Male sex, increasing age, RA and LA enlargement, and moderate/severe tricuspid regurgitation were previously shown to be predictors of AA. 4, 7, 14 By themselves, these fairly common characteristics do not warrant increased and potentially invasive monitoring for AA. In this present study, we characterized atrial structure and function using advanced tissue-tracking techniques to detect predictors of future AA. Higher atrial minimal volumes, decreased LA reservoir function (LAEF total and LA-PLAS), and RA conduit function (RAE-F passive and RA-SR ed ) were associated with increased risk of AA during follow-up. Therefore, atrial structural and functional parameters are important predictors of AA, independent of the overall disease severity and ventricular phenotype. Detecting early atrial remodeling in ARVC may offer an opportunity to prevent AA-related morbidity and mortality.
Limitations ARVC is a rare disease, and as such, our study has a small sample size. Our statistical analysis was also limited by number of outcome events. Although we performed multivariable survival analysis with 2 and 8 covariables, respectively (with no apparent bearings on the results), we cannot eliminate the possibility of overfitting in our analysis. Our results need to be validated in a large prospective study with longitudinal imaging data. In this study, most AAs were detected on ambulatory ECG, with a minority detected on ICD and Holter monitoring. Other studies have reported that a large proportion of AAs were diagnosed on implanted devices (both during routine follow-up and as a result of inappropriate shocks) and Holter monitors. This suggests that many AA in our population may be concealed. Therefore, we could have missed patients who had asymptomatic paroxysmal AA that was not detected during clinical follow-up. Scans of ARVC cases were performed in the Netherlands, whereas those of controls were done in the United States. Although protocols between the 2 institutions were identical (as mentioned in the Methods), temporal resolution was ≈45 ms for controls and 50 ms for cases-a small difference that is unlikely to have any significant impact on our results. In the absence of a single gold standard variable to evaluate atrial function, selecting one among all the acquired atrial function parameters on CMR seems arbitrary. We have thus opted to present the readers with a comprehensive summary of our findings with our best attempt at selecting the variable(s) with highest prognostic value, possibly introducing type I error. As mentioned previously, the link between AA and poor outcomes has been shown in previous studies. As such, the examination of prognostic value of atrial functional parameters, which predict AA, on ventricular tachycardia/ventricular fibrillation/mortality would be interesting to explore. However, we did not have the appropriate data to perform such prospective analysis.
Conclusions
Compared with controls, patients with ARVC were found to have enlarged atria with decreased function on functional CMR examination. RA and LA parameters predict incident AA after adjusting for clinical and ventricular characteristics which suggest atrial involvement in ARVC. 
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